13F Holdings
中文EN

CRSP CRISPR Therapeutics AG

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1674416 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-34.3%
TTM net income YoY6.6%
TTM EPS YoY14.6%
Revenue 3-yr CAGR-47.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,114.8%
Net margin-1,812.1%
FCF margin-1,496.6%
EBITDA margin-2,041.3%

Returns

ROE-25.6%
ROA-19.0%
ROIC (approx.)-22.9%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets35.5%
Debt / equity0.36x
Current ratio16.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue8.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$3.51M$37.31M$371.21M$1.20M$914.96M
R&D expense$284.81M$310.24M$387.33M$461.64M$340.57M
SG&A expense$73.54M$72.98M$76.16M$102.46M$99.69M
Operating income-$664.57M-$466.57M-$222.54M-$673.16M$373.53M
Pretax income-$577.97M-$362.67M-$150.72M-$650.50M$379.53M
Income tax$3.63M$3.59M$2.89M-$325,000$1.87M
Net income-$581.60M-$366.25M-$153.61M-$650.17M$377.66M
EBITDA-$645.09M-$447.31M-$202.70M-$648.99M$391.48M
EPS (basic)-6.47-4.34-1.94-8.364.97
EPS (diluted)-6.47-4.34-1.94-8.364.70
Weighted avg. shares (diluted)89.93M84.36M79.22M77.75M80.39M
Balance sheet
Cash & equivalents$347.56M$298.26M$389.48M$211.88M$923.03M
Short-term investments$1.63B$1.61B$1.30B$1.60B$1.46B
Receivables$0$25.00M$200.00M$0$305,000
Current assets$1.99B$1.94B$1.91B$1.85B$2.42B
PP&E, net$115.85M$134.09M$151.94M$163.63M$137.57M
Intangibles—$0$16,000$71,000$125,000
Total assets$2.27B$2.24B$2.23B$2.24B$2.75B
Current liabilities$149.12M$87.78M$108.79M$121.11M$119.88M
Long-term debt$0————
Total debt$0————
Total liabilities$343.43M$309.95M$346.77M$367.58M$352.42M
Shareholders' equity$1.92B$1.93B$1.88B$1.88B$2.40B
Net debt-$347.56M————
Shares outstanding95.89M85.74M80.04M78.51M76.99M
Cash flow statement
Operating cash flow-$345.01M-$142.77M-$260.38M-$495.74M$538.97M
Capital expenditure$914,000$1.90M$9.47M$37.19M$81.70M
Free cash flow-$345.93M-$144.68M-$269.85M-$532.93M$457.27M
Investing cash flow-$31.80M-$280.48M$374.65M-$258.65M-$1.04B
Financing cash flow$426.03M$331.98M$62.66M$38.59M$250.94M
Depreciation & amortization$19.48M$19.26M$19.84M$24.17M$17.95M
Stock-based compensation$72.50M$86.57M$81.03M$97.95M$102.39M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.